Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:sonidegib
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XX45
|
| gptkbp:brand |
gptkb:Odomzo
|
| gptkbp:CASNumber |
956104-40-8
|
| gptkbp:chemicalFormula |
C26H26N4O3
|
| gptkbp:form |
capsule
|
| gptkbp:genericName |
gptkb:sonidegib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Odomzo
|
| gptkbp:indication |
locally advanced basal cell carcinoma
patients not candidates for surgery or radiation |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
hedgehog pathway inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue weight loss alopecia decreased appetite dysgeusia muscle spasms |
| gptkbp:usedFor |
basal cell carcinoma
|
| gptkbp:bfsParent |
gptkb:Sun_Pharma
|
| gptkbp:bfsLayer |
6
|